Durban – Aspen, a global multinational specialty pharmaceutical company, was extremely disappointed to learn over the past weekend that specific batches of the Johnson & Johnson COVID-19 vaccine manufactured at our Gqeberha production site and designated for the South African market have to be destroyed due to the Good Manufacturing Practice risk of isolated material… Continue reading Aspen statement on manufacture and supply of COVID-19 vaccines
Aspen will be in a closed period from 1 January 2025 until the publication of the Interim Results on the JSE SENS platform on 3 March 2025.
